Medicare to Offer $50 Monthly GLP-1 Access for Weight Management Starting July

Some Medicare beneficiaries will be able to obtain GLP-1 medications for a flat $50 monthly copay beginning July 1, 2026. The temporary demonstration runs through December 31, 2027, and is limited to weight-management use. The Centers for Medicare and Medicaid Services described the Medicare GLP-1 Bridge as a time-limited demonstration.

Eligible enrollees must be in a standalone prescription drug plan, a Medicare Advantage coordinated care plan, or certain other Part D plan types.

Beneficiaries must be at least 18 years old and have a body mass index of 27 or higher. They must also have at least one qualifying condition such as prediabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease. Higher BMI thresholds require additional diagnoses including heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a or above.

The medications covered are Wegovy, Zepbound, and Foundayo. A medical provider must submit a prior authorization request and prescription. The claim is then routed to a central processor referred to as the Bridge PCN. The $50 copay does not count toward deductibles or out-of-pocket maximums.

The program does not require additional beneficiary paperwork beyond obtaining a prescription. Officials have not released cost estimates or enrollment projections. A CMS spokesperson stated that the demonstration operates outside standard Part D coverage and payment rules.

Regulatory observers have raised questions about potential fraud or misuse through telehealth prescribing. One healthcare regulatory counsel noted that the prior-authorization requirement creates coordination between provider and pharmacy but said fraud remains possible.